News

The founder and chief scientific officer of Neurolutions discussed how the company’s newly approved chronic stroke rehabilitation system will provide expanded benefits to post-stroke patients.

The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.

Understanding the signs and symptoms stroke during National Stroke Awareness Month.

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).

A poster presentation at the American Psychiatric Association Virtual Meeting suggests that late-life depression might predict self-reported cognitive complaints.

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

The partnership combines Capsigen’s vector engineering with Biogen’s drug pipeline, seeking to develop gene therapies for neuromuscular and central nervous system disorders.

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.

Sleep depth was observed to be an independent predictor of heart rate change following seizure for patients with epilepsy.

Kathy Zackowski, PhD, OTR, senior director of patient management, care, and rehabilitation research at the National MS Society discussed her team’s call to action for research.

A recent study showed improvements in animals with mutant huntingtin protein treated with AFFiRiS AG’s investigational monoclonal antibody.

Improvements in DMTs and management standards appear to have lowered the risk of progression to EDSS scores of 4.0 and 6.0 for those with pediatric-onset disease.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how novel dexterity measurements can improve prognostication of disease progression.

Daniel Reich, MD, PhD, senior investigator at the National Institutes of Neurological Disorders and Stroke, spoke about his investigations into the role of microglia in progressive MS.

The associate professor of neurology at Columbia University and medical consultant and care center director at the Muscular Dystrophy Association spoke to the importance of staying up on the latest developments in ALS and keeping patients in the loop on that information.

Here's what is coming soon to NeurologyLive.

The associate professor of neurology at Columbia University and medical consultant and care center director at the Muscular Dystrophy Association discussed the use of larger datasets to improve prognostication and clinical trials in ALS.

A recent study identified 3 novel loci that are associated with Parkinson disease progression to dementia: RIMS2, TMEM108, and WWOX.

The Epilepsy Digital Experience Navigator, or EDEN, platform, is being developed in tandem with Embleema, with an aim of improving data use and collection for individuals with epilepsy.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed his team’s efforts to find the minimally effective dose of IMU-838.

Spencer Hutto, MD, a fellow of autoimmune neurology at Massachusetts General Hospital, discussed his team’s investigation into demyelinating events after the use of TNFαi inhibitors.

Neurology News Network for the week ending May 8, 2021.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his team’s investigations presented at the 2021 AAN Annual Meeting.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

Paula K. Schweitzer, PhD, discussed her findings on the safety and efficacy of solriamfetol in patients receiving OSA therapy and the need for more research on residual excessive daytime sleepiness.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the ways clinicians can tailor their treatment regimens better.

Didactic lectures were the most commonly used teaching format by all specialties, with pulmonary and critical care medicine and neurology reporting the highest hours of attendance.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.